Navigation Links
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
Date:8/5/2008

------------------ ----------------

Jun. 30, Jun. 30,

-------- --------

2008 2007 2008 2007

---- ---- ---- ----

GAAP net income (loss) $4,474 $(10,826) $19,892 $(23,021)

Non-GAAP adjustments:

Employee stock-based compensation

under FAS 123R $4,253 $3,634 $9,469 $6,626

------ ------- ------- --------

Non-GAAP net income (loss) (3) $8,727 $(7,192) $29,361 $(16,395)

------ -------- ------- ---------

GAAP diluted net income (loss) per

share $0.08 $(0.22) $0.35 $(0.49)

Non-GAAP adjustments:

Employee stock-based compensation

under FAS 123R $0.07 $0.07 $0.17 $0.14

------ ------ ------ ------

Non-GAAP diluted net income (loss)

per share (3) $0.15 $(0.15) $0.52 $(0.35)

------ ------ ------ -------

Diluted shares 56,472 48,242 56,534 47,265

(3) This press release includes the following non-GAAP financial

measures: non-GAAP net income (loss) and non-GAAP diluted net income

(loss) per share, both of which exclude the impact of employee stock-based

compensation expense. The foregoing table reconciles these non-GAAP

measures to the most comparable financial measures calculated in

accordance with GAAP.

Our management uses these non-GAAP financial measures to monitor and

evaluate our operating results and trends on an on-
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 - New Massive Open ... prepare for the United States Medical Licensing Examination ... technical and medical information products and services, announced today ... Online Course) designed to help medical students prepare for ... the first and most daunting of the three exams ...
(Date:5/4/2015)...   Intrexon Corporation (NYSE: XON ) ... results after the market closes on May 11, 2015.  ... at 5:30 PM ET to discuss the results and ... call may be accessed by dialing 1-888-346-3959 (Domestic US) ... Conference Call."  Participants may also access the live webcast ...
(Date:5/4/2015)... May 04, 2015 Marianjoy ... patients with arm and hand impairments by acquiring ... its Oakbrook Terrace network site. , Secured through ... is a highly-regarded treatment option for patients with ... Armeo®Spring, Marianjoy becomes one of just four Illinois ...
(Date:5/1/2015)... 01, 2015 OncoTAb, Inc., ... spin-out company, announced that Pinku Mukherjee, Ph.D. has received ... Board of Governors’ highest faculty honor. Mukherjee received the ... , for her innovative research and development of cancer ... represents a crowning moment in my scientific career,” said ...
Breaking Biology Technology:Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Charles Drew University of Medicine and Science and UC ... and their parents as part of a comprehensive initiative ... Karen Cheng, CDU psychiatry and human behavior ... a $480,000 grant from the Robert Wood Johnson Foundation ...
... This release is available in Spanish . ... and gaining nutrition savvyplus physical fitness skillsare emerging from ... For example, investigators Craig A. Johnston, John P. ... upon one of their earlier studies in which many ...
... scientists in the United Kingdom and the Netherlands ... become progressively more resistant to antibiotics over the ... apparent more stringent rules on use of antibiotics ... technology that broadly improves water quality in surrounding ...
Cached Biology News:Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 2Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 3Kids lose pounds, gain fitness in Houston study 2
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
...
Biology Products: